
Ligand Pharmaceuticals Incorporated LGND
$ 120.22
-1.47%
Quarterly report 2024-Q3
added 11-08-2024
Country |
![]() |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Mr. John Higgins |
Employees in the company |
115 |
Shares |
17.3 M |
Market Cap[1] |
$ 2.08 B |
EBITDA (LTM) |
$ 124 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.